Lundbeck’s Vyepti Sales Disappoint But Lower Costs Boost Profitability

Danish Firm Hoping For More From Migraine Drug

09 Feb 2022

• By Ayisha Sharma

Sales for the migraine product were lower in Q4 than consensus forecasts projected, but reduced costs have pushed yearly earnings beyond expectations.

Migraine, conceptual computer illustration. — Migraine Drug Vyepti Had Been Touted As Transformational For The Firm • Source: Alamy

H. Lundbeck A/S’s 2021 financials disappointed some analysts as regards Q4 sales of the migraine preventative Vyepti but lower costs have given the Danish company’s overall profits a helping hand.

While global Vyepti (eptinezumab) revenues totaled DKK492m ($65.9m) last year, up from DKK93m in 2020, J.P. Morgan analysts said that...